Pipeline and clinical programs for neurological disorders
Neurological Indications (use case IP & formulation IP)
Psychedelic based therapeutics have been studied extensively in various neurological indications, with focuses on the mental health illness such as depression and pain. Our natural formulation of psychedelic will follow FDA’s botanical drug guidelines and be investigated in patients to treat the symptoms in traumatic brain injury (TBI), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). Investigational new drug (IND) filling is planned in the second half of 2023.
Novel combinatorial synergistic therapy (combination IP)
In our pursuit of combinatorial and synergistic therapy for better efficacy in treatment of neurological patients, we are developing innovative therapeutics that combines proven mechanism of actions with new discoveries in psychoplastogens and their ability to promote neuroplasticity and neuro-rejuvenation. Intended for stroke and Parkinson's disease, the study application is expected to be submitted in the first half of 2024.